2026年度格隆汇"全球视野"十大核心资产已正式发布，汇丰控股经过层层选举和PK最终入选成为"全球 视野"十大核心资产中金融行业代表标的。 以下是关于汇丰控股的入选原因和分析逻辑： 当全球货币政策逐步转向宽松，跨境贸易与资本市场暖意渐浓，跨国银行正站在战略聚焦与业绩复苏的 十字路口。汇丰控股（HSBC.US）用三年时间完成了一场深刻转型——剥离欧美低盈利零售资产，将 重心重新锚定亚太市场，深耕"零售银行+跨境贸易+财富管理"的协同优势，凭借百年积累的区域网络 与清晰的战略方向，成为2026年全球核心资产中不可忽视的标的。 2025年前三季度，这份转型成效已清晰显现：净息差收入同比增长4%，剔除特殊项目后的权益回报率 （RoTE）高达18.2%，四大核心业务板块全部实现正向增长。随着非核心业务包袱出清，成本优化逐步 落地，汇丰正从传统跨国银行向"亚太核心+高现金回报"的优质标的转型，在降息周期中的抗风险能力 与业绩弹性，值得长期关注。 01 降息周期下的行业机遇：亚太市场成核心增量引擎 全球银行业在经历2022-2023年的利率波动后，2024年迈入稳健复苏通道，2025年呈现明显结构性分化 ——亚太地区成为全 ...

2025年，中国资本市场浪潮奔涌，证券公司作为核心中介与市场"看门人"，其发展轨迹深刻牵动着金融 生态的稳定。证监会对证券行业"长牙带刺、有棱有角"的监管态度一以贯之，视合规管理为行业发展的 重要因素，以"零容忍"姿态打击违法违规行为，彰显了守护资本市场根基的坚定决心。 监管高压下，违规代价愈发凸显。截至2025年末，81家券商机构累计收到181张罚单，400名从业人员被 监管采取了监管措施，更有1.35亿元的巨额罚单指向违规券商高管。 合规风控是券商的"生命线"，这既是证监会的反复警示，也是行业发展的必然选择。从修订《证券发行 与承销管理办法》到出台分类评价新规，监管通过制度完善和"扶优限劣"机制，引导行业筑牢合规防 线。对于券商而言，唯有将合规嵌入业务全流程，强化内控管理，才能在高压监管下实现稳健发展，既 守护自身长远前景，也为资本市场高质量发展提供坚实保障。 81家券商机构被罚 国泰海通数量居首 经梳理Wind数据，南都·湾财社记者注意到，截至2025年末，81家券商机构（含分支机构或营业部）收 到共计181张罚单。具体来看，国泰海通收到的罚单数量最多，达到7张；申万宏源和申万宏源承销保荐 分别收到3张 ...

总体来看，这份年度评价清晰地传递出一个信号：在监管持续压实"看门人"责任的背景下，业务的合规质量与内控水平，其重 要性已超越单纯的规模排名，正在逐渐重塑券商投行业的竞争格局与生态。 逆袭与掉队：12家A类半数非巨头，罚单拖累头部玩家 12月30日，中证协同时发布了2025年证券公司投行业务三项质量评价结果——投行业务质量评价、债券业务执业质量评价以及 财务顾问业务执业质量评价。评价周期均为2024年1月1日至12月31日。 21世纪经济报道 记者 崔文静 实习生 张长荣 临近年末，券商投行业务的年度"体检报告"如期公布。2025年12月30日，中国证券业协会一次性发布了覆盖投行全链条的三项 执业质量评价结果，对2024年度券商的投行业务、债券业务及财务顾问业务进行了一次全面的"扫描"与"定级"。 在这份备受关注的评价清单中，一些固有认知被打破。最综合的投行业务质量评价上演了"非头部逆袭"：12家A类券商中，半数 并非传统意义上的营收利润前十巨头，国金、东吴、长城等腰部券商凭借稳健表现成功跻身最高梯队。与之形成鲜明对比的 是，中信建投（601066）等实力派选手却因过往罚单拖累，止步于B类。 债券业务的评价则揭 ...

Core Viewpoint - The China Securities Association (CSA) has released the results of the evaluation of the underwriting business, bond business, and financial advisory services of securities firms, aiming to enhance the quality of practice and better serve the real economy and new productive forces [1][8]. Group 1: Evaluation Results - The evaluation of underwriting business included 93 securities firms, with results categorized into A, B, and C grades: 12 firms received A, 66 received B, and 15 received C [1][4]. - The bond business evaluation covered 95 firms, resulting in 14 firms rated A, 62 rated B, and 19 rated C [4][6]. - For the financial advisory services related to major asset restructuring, 30 firms participated, with 5 rated A, 19 rated B, and 6 rated C [6][8]. Group 2: Evaluation Criteria - The evaluation categories reflect the relative levels of practice quality, internal control systems, and service capabilities in underwriting, bond issuance, and financial advisory services, without assessing the creditworthiness or business qualifications of the firms [3][4]. - The CSA aims to guide firms to shift from price competition to value competition, enhancing the professionalism and influence of their underwriting services [8]. Group 3: Future Directions - The CSA plans to revise the evaluation indicators to further improve the quality of practice and guide firms towards function-oriented operations [8].

聚焦格局更优的细分领域——证券行业 2026 年度投资策 略 20251228 摘要 2025 年券商板块整体跑输金融子行业，估值从年初高位回落至 1.4 倍 左右，但前三季度全上市券商利润增速超过 60%，主要由经纪业务和自 营业务驱动。 头部券商如东方财富、中信证券、国信证券、银河证券等 ROE 领先优势 显著，2025 年达到 9%-10%左右，中金公司、申万宏源、长江证券等 公司的 ROE 提升幅度也很明显。 预计 2026 年资本市场延续慢牛行情，自营业务和经纪业务将支撑行业 ROE，但佣金率将继续下滑，预计从去年末万分之一点九五降至今年末 万分之一点七左右。 投行、资管及国际业务是值得关注的细分领域，盈利复苏滞后于市场好 转，目前仍处于周期底部，有望随着市场修复而逐步复苏，且国际业务 增长迅速但占比仍低。 2025 年 A 股 IPO 市场仍然紧缩，强调投融资平衡，IPO 数量和规模较 小，2023 年底以来的 IPO 暂停状态延续，港股 IPO 及再融资规模恢复 较快，但盈利弹性不及 A 股。 Q&A 2026 年证券行业的投资策略是什么？ 2026 年的证券行业投资策略主要聚焦在格局更优的细分 ...

Core Viewpoint - The article highlights the significant growth and strategic initiatives of Guolian Minsheng Securities in supporting private technology innovation enterprises, particularly in the Yangtze River Delta region, showcasing successful case studies like Haofan Bio and Haoyuan Pharmaceutical [5][6][17]. Group 1: Financial Performance - Guolian Minsheng's investment banking business reported a net income of 688 million yuan for the first three quarters of 2025, marking a year-on-year increase of 160.77% [5]. - The company's bond underwriting scale reached 48.38 billion yuan, reflecting a year-on-year growth of 147.5%, significantly outpacing industry growth rates [5]. Group 2: Company Initiatives - Haofan Bio is expanding its production capacity by 3 to 4 times with a new 230-acre facility set to be operational by June 2026 [5]. - Haoyuan Pharmaceutical is establishing five high-activity GMP production lines at its research center in Ma'anshan, aiming to accelerate the development of new molecular drugs [5][6]. Group 3: Industry Strategy - Guolian Minsheng emphasizes a strategy of "deep regional engagement + industry specialization," which has proven effective in addressing the challenges faced by private technology innovation enterprises [6][8]. - The firm has established 12 industry groups within its investment banking department to enhance its research capabilities and provide specialized services [8]. Group 4: Market Positioning - The article notes that Haofan Bio and Haoyuan Pharmaceutical are leaders in their respective fields, with a focus on long-term growth and innovation [11][17]. - Guolian Minsheng's investment banking team has successfully assisted Haoyuan Pharmaceutical in completing its initial public offering (IPO) and subsequent strategic initiatives, including mergers and acquisitions [12]. Group 5: Regional Focus - The Yangtze River Delta region is highlighted as a key area for technology innovation, with Guolian Minsheng actively providing financial services tailored to local industry needs [14][16]. - The firm aims to support high-quality development in the region by focusing on sectors such as biomedicine, semiconductors, artificial intelligence, and new energy [16][17].

证 券 研 究 报 告 南京证券（601990）深度研究报告 推荐（首次） 业务矩阵齐发力，区域国资强赋能 目标价：9.45 元 [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 3,147 | 3,315 | 3,629 | 3,894 | | 同比增速(%) | 27% | 5% | 9% | 7% | | 归母净利润(百万) | 1,002 | 1,242 | 1,369 | 1,462 | | 同比增速(%) | 48% | 24% | 10% | 7% | | 每股盈利(元) | 0.27 | 0.34 | 0.37 | 0.40 | | 市盈率(倍) | 29.4 | 23.6 | 21.4 | 20.0 | | 市净率(倍) | 1.64 | 1.57 | 1.51 | 1.46 | 资料来源：公司公告，华创证券预测 注：股价为 2025 年 12 月 24 日收盘价 公司研究 证券Ⅲ 2025 年 12 月 25 日 | ...

从一家区域性券商，到总资产近两千亿的金融旗舰，国联民生证券以一场深刻的市场化改革与一桩标志 性的战略并购，完成了自身基因的重塑与能级的跃迁。 作为植根江苏、辐射全国的综合类券商，国联民生证券始终将服务国家战略、赋能实体经济视为己任， 以专业与创新为双翼，在中国资本市场深化改革的壮阔画卷中，刻下了属于自己的奋进坐标。 与时代同频 区域性券商"破茧成蝶" 长江之水，奔流不息。在这片改革开放的前沿阵地上，国联民生证券自诞生之日起，便将血脉深深融入 国家经济发展的宏大叙事。三十余载风雨兼程，国联民生证券的每一次跨越，都精准踏在了中国经济转 型升级的节拍上。 2019年，当中国资本市场改革的春潮暗涌时，太湖之畔的国联证券（现更名为"国联民生证券"），已然 听到了时代的召唤。 这是一场深刻的价值嬗变。国联民生证券刀刃向内，全方位市场化改革。公司清晰地认识到，唯有主动 融入国家金融发展战略，才能在行业的洗牌与重构中赢得一席之地。 "成为一家公司治理优良、盈利能力强、在部分领域具备显著经营特色的精品中大型券商。"这一写 在"十四五"规划开篇的愿景，成为了改革的总航标。 "补短板"是改革的第一声号角。资本、机制、人才、业务，四 ...

对2023年至今四家上市券商并购流程复盘，合并启动、股票复牌至第一次监管审核期间，定价方案托 底，整合与协同预期利好估值相对行业上行，后逐渐回归基本面定价。中金并购拉开"汇金系"券商整合 序幕，复牌后仍待交易所、证监会审核及董事会、股东大会审议未决事项。 中长期，1+1+1>3助力中金公司加速建设一流投行 广发证券主要观点如下： 短期来看，整合方案托底股价预期，合并流程释放利好催化 广发证券发布研报称，预计中金公司（601995）(03908)2025-2026年归母净利润81.3/94.7亿元，鉴于19- 21年公司H股PB均值中枢为1.1倍，考虑景气度上行及公司加速整合释放协同效应，给予H股2026年1倍 PB估值，合理价值为28.43港元/股，维持H股"买入"评级。(HKD/CNY=0.93)(如无特别说明，本报告货 币单位为人民币) (3)投行业务延伸企业客户服务全周期价值链，打造不良资产协同增长竞争力。中金公司品牌及国际化 优势突出，长期在服务中资企业全球IPO、服务中资企业境外债券承销规模中保持中资券商第一。合并 实现规模叠加与功能战略互补，有望拓展特殊资产与另类投资新蓝海。 风险提示：行业竞争加 ...

Core Viewpoint - The merger of CICC with Dongxing Securities and Cinda Securities is expected to lead to a significant revaluation of the entire securities industry, enhancing CICC's competitive position and market share while benefiting from potential regulatory relaxations and new business opportunities [1][3][15]. Group 1: Market Reaction - Following the announcement of the merger, CICC and Dongxing Securities saw their A-shares hit the daily limit, while Cinda Securities rose by 6.8%, indicating a positive market sentiment towards the merger [1]. - Despite some fluctuations in stock prices due to market sentiment, the overall expectation for industry consolidation remains optimistic, suggesting a potential revaluation of the securities sector [1]. Group 2: Strategic Implications - The merger marks the beginning of a deeper integration phase in China's securities industry, transitioning from simple asset and capital scale expansions to a focus on enhancing professional capabilities and creating a complementary business ecosystem [3][12]. - CICC's total assets are projected to exceed 1 trillion yuan post-merger, elevating its industry ranking from sixth to fourth, and positioning it among the top tier of investment banks [4][5]. Group 3: Financial Strength and Efficiency - The merger will double CICC's capital base, significantly enhancing its financial strength and operational efficiency, with CICC's average financial investment return rate at 3.5%, outperforming its peers [5][6]. - The merger allows CICC to leverage the more stable leverage ratios of Dongxing and Cinda, creating additional capital allocation and business expansion opportunities [5]. Group 4: Business Integration Highlights - The merger will increase CICC's branch network from 245 to 436, enhancing regional coverage and customer base, with retail clients expected to exceed 14 million, marking a growth of over 50% [8][9]. - CICC's wealth management capabilities will be strengthened through the integration of its buy-side advisory model with the regional client bases of Dongxing and Cinda, facilitating a new phase of scalable growth in wealth management [10]. - The traditional strengths of CICC in investment banking will be further enhanced, with an increase in the number of A-share sponsors and improved capabilities in handling special asset management and restructuring [11]. Group 5: Industry Transformation - The merger represents a shift in the valuation logic of the securities industry, moving from a focus on cyclical performance to recognizing the strategic importance of leading investment banks in national economic development [15][16]. - Analysts predict that the merger will ignite investment enthusiasm in the securities sector, with expectations of improved valuations and profitability driven by a more favorable market environment [13][17].